Pharmaceutical

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.

Aug 1, 2024 - 04:00
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.
Read the original article

Tags:

Previous Article

Magazine: Left in limbo: when pharma halts rare disease research

Next Article

Imunon’s shares soar after IL-12 therapy success in Phase II trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Zerva acquires Acer Therapeutics to bolster rare disease portfolio

Zerva acquires Acer Therapeutics to bolster rare diseas...

Sep 1, 2023

How the pharma industry can benefit from using modular real-time technology

How the pharma industry can benefit from using modular ...

Aug 14, 2023

FTC sues private equity firm Welsh Carson, U.S. Anesthesia Partners for allegedly creating a monopoly

FTC sues private equity firm Welsh Carson, U.S. Anesthe...

Sep 22, 2023